Revlimid and Warm type haemolytic anaemia - a phase IV clinical study of FDA data

Summary:

Warm type haemolytic anaemia is reported only by a few people who take Revlimid.

The phase IV clinical study analyzes which people take Revlimid and have Warm type haemolytic anaemia. It is created by eHealthMe based on reports of 331,128 people who have side effects while taking Revlimid from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 27, 2023

331,128 people reported to have side effects when taking Revlimid.
Among them, 2 people (0.0%) have Warm type haemolytic anaemia.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 331,426 Revlimid users for its effectiveness, alternative drugs and more.

What is Warm type haemolytic anaemia?

Warm type haemolytic anaemia (red cell destruction due to warm antibody self defence) is found to be associated with 176 drugs and 122 conditions by eHealthMe.

Number of Revlimid and Warm type haemolytic anaemia reports submitted per year:

Could Revlimid cause Warm type haemolytic anaemia?

Time on Revlimid when people have Warm type haemolytic anaemia *:

Gender of people who have Warm type haemolytic anaemia when taking Revlimid *:

female: 0.0 %
male: 100 %

Age of people who have Warm type haemolytic anaemia when taking Revlimid *:

Common drugs people take besides Revlimid *:

Pantoprazole: 1 person, 50.00%
Cotrim D.s.: 1 person, 50.00%
Actrapid: 1 person, 50.00%
Acetylsalicylic Acid: 1 person, 50.00%

Common conditions people have *:

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Warm type haemolytic anaemia?

Check whether Warm type haemolytic anaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Warm type haemolytic anaemia and when was it recovered:

Warm type haemolytic anaemia in Revlimid

Expand to all the drugs that have ingredients of lenalidomide:

Warm type haemolytic anaemia and drugs with ingredients of lenalidomide

Alternative drugs to, pros and cons of Revlimid:

Revlimid (331,426 reports)

Common Revlimid side effects:

Death: 24,344 reports
Diarrhea: 23,781 reports
Fatigue (feeling of tiredness): 21,089 reports
Multiple myeloma (cancer of the plasma cells): 17,070 reports
Pneumonia: 16,950 reports
Rashes (redness): 15,559 reports
Thrombocytopenia (decrease of platelets in blood): 14,033 reports
Weakness: 9,637 reports

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Warm type haemolytic anaemia treatments and more:

Warm type haemolytic anaemia (205 reports)

COVID vaccines that are related to Warm type haemolytic anaemia:

All the drugs that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (176 drugs)

All the conditions that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (122 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.